Nationwide Fund Advisors Holds Position in BioMarin Pharmaceutical Inc. (BMRN)

Nationwide Fund Advisors held its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,800 shares of the biotechnology company’s stock at the end of the second quarter. Nationwide Fund Advisors’ holdings in BioMarin Pharmaceutical were worth $2,797,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. TIAA CREF Investment Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 63.7% in the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after acquiring an additional 875,686 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 41.7% in the second quarter. Teachers Advisors LLC now owns 973,291 shares of the biotechnology company’s stock valued at $88,394,000 after acquiring an additional 286,249 shares in the last quarter. Seven Eight Capital LP grew its holdings in shares of BioMarin Pharmaceutical by 1,680.0% in the second quarter. Seven Eight Capital LP now owns 35,600 shares of the biotechnology company’s stock valued at $3,233,000 after acquiring an additional 33,600 shares in the last quarter. Fiera Capital Corp grew its holdings in shares of BioMarin Pharmaceutical by 1.6% in the second quarter. Fiera Capital Corp now owns 6,613 shares of the biotechnology company’s stock valued at $601,000 after acquiring an additional 101 shares in the last quarter. Finally, Symphony Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 1.1% in the second quarter. Symphony Asset Management LLC now owns 6,465 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 73 shares in the last quarter. 97.47% of the stock is owned by institutional investors.

In related news, EVP Robert Baffi sold 18,415 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the transaction, the executive vice president now owns 129,083 shares in the company, valued at approximately $11,931,141.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of BioMarin Pharmaceutical stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $95.00, for a total transaction of $334,495.00. Following the transaction, the executive vice president now owns 49,299 shares in the company, valued at approximately $4,683,405. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,686 shares of company stock worth $3,736,318. 1.85% of the stock is owned by corporate insiders.

BMRN has been the subject of several recent analyst reports. ValuEngine raised BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cowen and Company reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 11th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $115.00 target price (up from $111.00) on shares of BioMarin Pharmaceutical in a report on Thursday, July 13th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $115.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, July 14th. Finally, Zacks Investment Research raised BioMarin Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $105.00 target price for the company in a report on Monday, July 17th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $110.21.

Shares of BioMarin Pharmaceutical Inc. (BMRN) opened at 95.13 on Friday. The stock’s market cap is $16.67 billion. BioMarin Pharmaceutical Inc. has a 12 month low of $78.42 and a 12 month high of $100.51. The company has a 50 day moving average price of $91.36 and a 200-day moving average price of $89.94.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The company had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. During the same quarter in the previous year, the company earned ($2.61) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post ($0.72) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2017/10/13/nationwide-fund-advisors-holds-position-in-biomarin-pharmaceutical-inc-bmrn.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply